



## Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024

June 7, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jun. 7, 2024-- [Vistagen](#) (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced it will host a conference call and webcast on Tuesday, June 11, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 ended March 31, 2024 and provide a corporate update.

**Event:** Vistagen Fiscal Year 2024 Corporate Update Conference Call

**Date:** Tuesday, June 11, 2024

**Time:** 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time)

**US Dial-in (Toll-free):** 1-877-407-9716

**TOLL/International Dial-in:** 1-201-493-6779

**Conference ID:** 13746589

**Webcast:** [https://viaid.webcasts.com/starthere.jsp?ei=1670447&tp\\_key=0236806001](https://viaid.webcasts.com/starthere.jsp?ei=1670447&tp_key=0236806001)

An audio webcast of the conference call will also be available via the link provided above. Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 p.m. Pacific Time (8:00 p.m. Eastern Time) on Tuesday, June 11, 2024. To listen to the replay, call toll-free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay access ID number 13746589.

### About Vistagen

Vistagen (Nasdaq: VTGN) is a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders. Five of Vistagen's clinical-stage neuroscience pipeline candidates belong to a new class of drugs known as pherines, which are investigational neuroactive nasal sprays with innovative proposed mechanisms of action that activate chemosensory neurons in the nasal passages to impact fundamental neural circuitry in the olfactory system and the brain without the need for systemic absorption or binding to receptors in the brain. Vistagen's sixth investigational candidate is an oral prodrug with potential to modulate NMDA receptor activity. At Vistagen, we are passionate about delivering differentiated treatments that set new standards of care for people living with anxiety, depression, and other neurological disorders. Connect at [www.Vistagen.com](http://www.Vistagen.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240607082140/en/): <https://www.businesswire.com/news/home/20240607082140/en/>

#### Investors:

Mark A. McPartland

Vistagen Therapeutics

[markmcp@vistagen.com](mailto:markmcp@vistagen.com)

#### Media:

Caren Scannell

Vistagen Therapeutics

[cscannell@vistagen.com](mailto:cscannell@vistagen.com)

Source: Vistagen